WP-1066
- Generic Name
- WP-1066
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14BrN3O
- CAS Number
- 857064-38-1
- Unique Ingredient Identifier
- 63V8AIE65T
- Background
WP1066 has been used in trials studying the treatment of Melanoma, Brain Cancer, Solid Tumors, and Central Nervous System Neoplasms.
- Associated Conditions
- -
- Associated Therapies
- -
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R
Moleculin Biotech amends Phase 3 MIRACLE trial protocol with FDA, accelerating unblinding of preliminary primary efficacy data and safety/tolerability at 45 subjects, aiming for potential accelerated approval of Annamycin in combination with cytarabine for relapsed or refractory AML.
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute
Moleculin Biotech amends Phase 3 MIRACLE trial protocol with FDA, accelerating unblinding of preliminary efficacy data for Annamycin in R/R AML treatment, with first subject expected in Q1 2025.
Moleculin Biotech Accelerates Phase 3 AML Trial Data Timeline to H2 2025
Moleculin Biotech amends Phase 3 MIRACLE trial protocol with FDA, accelerating unblinding of preliminary efficacy data at 45 subjects for Annamycin in R/R AML treatment, aiming for potential accelerated approval and strategic partnering.
Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial
Moleculin Biotech received IRB approval for its Phase 3 MIRACLE trial evaluating Annamycin + Cytarabine for relapsed/refractory AML, aiming for first subject enrollment in Q1 2025.
Moleculin Biotech Advances Phase 3 Trial as Q3 Shows Mixed Financial Results
Moleculin Biotech reports Q3 2024 financial results, focusing on the advancement of Annamycin in the MIRACLE trial for R/R AML, with a median durability of CRc exceeding 8 months. The company plans to start dosing in the pivotal Phase 3 trial in Q1 2025 and expects key milestones through 2028, including potential NDA submission for accelerated approval.
Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Moleculin Biotech reports Q3 2024 financial results, plans to start dosing in the MIRACLE trial for Annamycin in Q1 2025, and highlights median durability of CRc in MB-106 Annamycin+Cytarabine AML clinical trial surpassing 8 months.
First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma
Moleculin Biotech announced the enrollment and treatment of patients in a Phase 2 study evaluating WP1066 combined with radiation therapy for glioblastoma, funded by NIH and BrainUp. The trial aims to assess progression-free survival and tumor microenvironment analysis, with initial data showing increased survival and anti-tumor immune responses.
Related Clinical Trials:
Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor
Moleculin Biotech announces enrollment and treatment of patients in a Phase 2 study evaluating WP1066 combined with radiation therapy for glioblastoma at Northwestern University, funded by NIH and BrainUp®. The trial aims to assess progression-free survival and tumor microenvironment analysis.
Related Clinical Trials:
Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3
Moleculin Biotech announces enrollment and treatment of patients in a Phase 2 study evaluating WP1066 combined with radiation therapy for glioblastoma at Northwestern University, funded by NIH and BrainUp®. The trial aims to assess progression-free survival and tumor microenvironment analysis.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath